An mRNA influenza vaccine bests an inactivated quadrivalent flu vaccine against two different strains in phase 3 study.

In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has ...

RNA, widely known from the COVID-19 vaccine, is not actually a "therapeutic agent," but a technology that delivers the ...

A recent study has provided the first side-by-side comparison of how three major COVID-19 vaccine types differ in triggering ...

The memo, written by FDA chief medical and scientific officer Vinay Prasad, reviewed 96 pediatric deaths and concluded that ...

Pfizer's mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 trial, researchers reported in the ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

The experimental mRNA vaccine prevented 60% to 67% of flu infections, while the conventional vaccine prevented 44% to 54% of infections, said Kelly Lindert, MD, vice president of clinical research and ...

Moderna is currently in the middle of an aggressive cost-cutting campaign. In September last year, the company announced that ...

Preclinical mRNA therapy using peptibodies enhances bacterial clearance and immune response in multidrug-resistant pneumonia ...

Researchers advance mRNA cancer therapies as France tests new methods, while the FDA approves Bayer’s Hyrnuo for HER2-mutated ...

A human-challenge randomized controlled trial, published last week in NEJM Evidence, finds that an mRNA (modRNA) influenza ...